Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain

INTRODUCTION: A subcutaneous (SC) formulation of natalizumab has been recently authorised for multiple sclerosis patients. This study aimed to assess the implications of the new SC formulation, and to compare the annual treatment costs of SC versus intravenous (IV) natalizumab therapy from both the...

Descripción completa

Detalles Bibliográficos
Autores principales: Alonso Torres, A. M., Arévalo Bernabé, A. G., Becerril Ríos, N., Hellín Gil, M. F., Martínez Sesmero, J. M., Meca Lallana, V., Ramió-Torrentà, Ll., Rodríguez-Antigüedad, A., Gómez Maldonado, L., Triana Junco, I., Gómez-Barrera, M., Espinoza Cámac, N., Oyagüez, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169937/
https://www.ncbi.nlm.nih.gov/pubmed/36802327
http://dx.doi.org/10.1007/s41669-023-00394-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169937/
https://www.ncbi.nlm.nih.gov/pubmed/36802327
http://dx.doi.org/10.1007/s41669-023-00394-2

Ejemplares similares